Forest's antibiotic Teflaro secures first approval, in US
This article was originally published in Scrip
Executive Summary
Forest Laboratories has secured its first approval, in the US, for its injectable broad-spectrum cephalosporin antibiotic Teflaro (ceftaroline fosamil), for the treatment of community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA). Forest expects Teflaro to be available to wholesalers by January 2011.